REDWOOD CITY,Calif., May 1, 2013 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that it will host an investor webcast and conference call to discuss the positive development and clinical validation study results of its biopsy-based Oncotype DX prostate cancer test on Wednesday, May 8, 2013 at 1:00 p.m. Pacific Time.
The event will feature members of the Genomic Health management team and the following distinguished urology experts:
- Peter R. Carroll, M.D., MPH, professor and chair, Department of Urology, UCSF and principal investigator for the UCSF Oncotype DX prostate cancer test validation study
- Matthew R. Cooperberg, M.D., assistant professor of Urology; Epidemiology and Biostatistics, UCSF and co-principal investigator for the UCSF validation study
- Eric A. Klein, M.D., chairman, Glickman Urological and Kidney Institute, Cleveland Clinic and principal investigator for the Cleveland Clinic Oncotype DX prostate cancer test development studies
Webcast and Conference Call Details
To access the live and subsequently archived webcast of the event including the slide presentation, go to the Investor Relations section of the company's website at http://investor.genomichealth.com. Please connect to the website at least 15 minutes prior to the call to allow for any software download that may be necessary.
To access an audio only feed of the live event, please dial 877-407-1869 from the United States or Canada and +1-201-689-8044 internationally. Please dial in approximately ten minutes prior to the start of the call.
About Genomic Health
Genomic Health, Inc. (NASDAQ: GHDX) is a global healthcare company that provides actionable genomic information to personalize cancer treatment decisions. The company's lead product, the Oncotype DX® breast cancer test, has been shown to predict the likelihood of chemotherapy benefit as well as recurrence in invasive breast cancer and has been shown to predict the likelihood of recurrence in ductal carcinoma in situ (DCIS). In addition to this widely adopted test, Genomic Health provides the Oncotype DX colon cancer test, the first multi-gene expression test developed for the assessment of risk of recurrence in patients with stage II and stage III disease. As of December 31, 2012, more than 19,000 physicians in over 70 countries had ordered approximately 335,000 Oncotype DX tests. Genomic Health has a robust pipeline focused on developing tests to optimize the treatment of prostate and renal cell cancers, as well as additional treatment decisions in breast and colon cancers. The company is based in Redwood City, California with European headquarters in Geneva, Switzerland. For more information, please visit, www.GenomicHealth.com. To learn more about the Oncotype DX tests, visit: www.OncotypeDX.com and www.mybreastcancertreatment.org.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the planned presentation of the clinical validation data for the Company's Oncotype DX test for prostate cancer at the AUA meeting; the attributes and focus of the company's product pipeline; the applicability of clinical study results to actual outcomes; the potential economic benefits associated with the company's tests; the ability of the company to develop additional tests in the future; the demand for the company's tests; the ability of any potential tests the company may develop to optimize cancer treatment and the Company's ability to launch new tests in new markets and expand internationally. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: the results of clinical studies; the applicability of clinical study results to actual outcomes; our ability to develop and commercialize new tests; unanticipated costs or delays in research and development efforts; the risks and uncertainties associated with the regulation of the company's tests and the other risks set forth in the company's filings with the Securities and Exchange Commission, including the risks set forth in the company's Annual Report on Form 10-K for the year ended December 31, 2012. These forward-looking statements speak only as of the date hereof. Genomic Health disclaims any obligation to update these forward-looking statements.
NOTE: The Genomic Health logo, Oncotype, Oncotype DX, Recurrence Score, and DCIS Score are trademarks or registered trademarks of Genomic Health, Inc. All other trademarks and service marks are the property of their respective owners.
SOURCE Genomic Health, Inc.